(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 14.84% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.45%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 14.82%.
Astrazeneca's revenue in 2020 is $25,871,000,000.On average, 2 Wall Street analysts forecast AZN's revenue for 2021 to be $40,710,048,000,000, with the lowest AZN revenue forecast at $39,949,088,000,000, and the highest AZN revenue forecast at $41,471,008,000,000. On average, 2 Wall Street analysts forecast AZN's revenue for 2022 to be $46,318,192,000,000, with the lowest AZN revenue forecast at $45,450,304,000,000, and the highest AZN revenue forecast at $47,186,080,000,000.
In 2023, AZN is forecast to generate $51,406,128,000,000 in revenue, with the lowest revenue forecast at $50,691,744,000,000 and the highest revenue forecast at $52,120,512,000,000.